T-Cell Prolymphocytic Leukemia

hematologic malignancy

Identifier: CI-CAN-00006875
Entity page: /cancer/t-cell-prolymphocytic-leukemia ↗
Edges: 43

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
T-Cell Prolymphocytic Leukemia investigated for …INVESTIGATED_FOR3 of 3
← investigated for	Venetoclaxsmall_molecule	unknown	2	T-Cell Prolymphocytic Leukemia	1	Curated	chembl	graph →
← investigated for	Ibrutinibsmall_molecule	unknown	2

T-Cell Prolymphocytic Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived16 of 16show fewer
→ investigated in trials for	Fludarabinesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Alemtuzumabmonoclonal_antibody 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ruxolitinibsmall molecule 3 trials (3 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall_molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Carmustinesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Duvelisibsmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Cladribinesmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall_molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Romidepsinother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Sirolimussmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →

T-Cell Prolymphocytic Leukemia investigated in trials for …INVESTIGATED_IN_TRIALSderived16 of 16show fewer

→ investigated in trials for

Fludarabinesmall molecule

6 trials (0 active) · roll-up of the cancer and its descendants

—

T-Cell Prolymphocytic Leukemia studied in …STUDIED_INderived10 of 24show all (up to 200)
→ studied in	NCT05010005Phase 1 · recruiting A Study of Ruxolitinib and Duvelisib in People With Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07311746Phase 1/Phase 2 · recruiting Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05377827Phase 1 · suspended Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06810778Phase 1/Phase 2 · recruiting Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05978141recruiting A Registry for People With T-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04771572Phase 1 · recruiting Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT07356245Phase 2 · recruiting Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT04496349Phase 2 · recruiting A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL · condition mapped ALIAS · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02512497Phase 1 · completed Romidepsin Maintenance After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05823571Phase 1 · active not recruiting Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients · condition mapped ONTOLOGY_EXACT · 24 trials mapped (9 active)	—	—	T-Cell Prolymphocytic Leukemia	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains